单剂裸盖菇素治疗伴严重治疗抵抗的抑郁症:一项开放标签试验
在Sheppard Pratt医院开展的12周开放标签试验中,12例对至少5种治疗应答不足的严重治疗抵抗抑郁症患者接受单剂合成裸盖菇素25 mg,第3周MADRS最小二乘均值变化-15.8(95% CI -25.4至-6.3),第12周-17.2(95% CI -25.2至-9.1),合并创伤后应激障碍(PTSD)者(N=5)抗抑郁效应显著较低,作者认为提示有效性与安全性并支持进一步研究。
要点
- 12例严重治疗抵抗抑郁症患者单剂裸盖菇素25 mg后第3周MADRS最小二乘均值变化-15.8(95% CI -25.4至-6.3)。
- 第12周MADRS最小二乘均值变化-17.2(95% CI -25.2至-9.1),抑郁症状显著下降。
- 合并PTSD的5例患者抗抑郁效应显著较低,探索性分析中神秘体验的Oceanic Boundlessness维度与应答相关。
核心结论
- 这项开放标签研究提示裸盖菇素在严重治疗抵抗抑郁症中具有有效性与安全性,并支持在该人群进一步研究致幻剂,包括考虑PTSD交互效应。
研究设计与样本
- 12周开放标签试验,在Sheppard Pratt医院开展,纳入18-65岁、当前抑郁发作且至少5种治疗获益不足的严重治疗抵抗抑郁症患者。
- 单剂合成裸盖菇素25 mg给药,精神药物在给药前至少2周至给药后至少3周停用,治疗师在 pretreatment、8小时给药日及 posttreatment 共进行三次会谈与三次整合会谈。
主要发现
- 12例参与者(6男6女;平均年龄40.6岁[SD=9.6])完成随访,第3周MADRS最小二乘均值变化-15.8(95% CI -25.4至-6.3)。
- 第12周MADRS最小二乘均值变化-17.2(95% CI -25.2至-9.1)。
- 探索性分析中,致幻体验的Oceanic Boundlessness(OB)维度与给药后抗抑郁应答相关。
- 合并PTSD的5例患者(N=5)显示裸盖菇素抗抑郁效应显著较低。
关键数值与推荐
- 主要结局为治疗后第3周蒙哥马利-奥斯伯格抑郁评定量表(MADRS)评分变化。
- 次要结局包括截至第12周的MADRS评分及基线至后续各访视的患者自评抑郁与功能量表。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为开放标签研究,未设盲法或对照。
- 样本量为12例,合并PTSD亚组仅5例。
- 作者结论称需进一步研究致幻剂在该人群中的应用,包括考虑PTSD交互效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Depression varies along a difficulty-to-treat spectrum. Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD). The objective of this study was to document the safety and efficacy of psilocybin in patients with severe TRD. METHODS: This was a 12-week, open-label trial conducted at Sheppard Pratt Hospital. Participants were 18-65 years of age, in a major depressive episode with documented insufficient benefit from at least five treatments during the current episode. A single dose of synthetic psilocybin (25 mg) was administered. Psychotropic medications were discontinued at least 2 weeks prior to dosing through at least 3 weeks post-dosing. Therapists met with patients for three sessions during pretreatment, during the 8-hour dosing day, and for three integration sessions posttreatment. The primary outcome measure was change in Montgomery-Åsberg Depression Rating scale (MADRS) at 3 weeks posttreatment. Secondary measures including MADRS scores up to 12 weeks posttreatment, and subject-rated scales capturing depression and level of function were completed at baseline and all subsequent visits. RESULTS: Twelve participants (six male, six female; mean age=40.6 years [SD=9.6]) with severe TRD were followed over the study period. Depressive symptoms were significantly decreased at week 3 (MADRS least-squares mean change=-15.8, 95% CI=-25.4 to -6.3) and Week 12 (MADRS least-squares mean change=-17.2, 95% CI=-25.2 to -9.1). In exploratory analyses, the Oceanic Boundlessness (OB) dimension of the psychedelic experience correlated with post-dosing antidepressant responses. Patients with comorbid PTSD (N=5) showed significantly less antidepressant effect of psilocybin. CONCLUSIONS: This open-label study suggests efficacy and safety of psilocybin in severe TRD and supports further study of psychedelics in this population, including consideration of PTSD interaction effects.
引用
- Aaronson ST, van der Vaart A, Miller T, et al. Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial. Am J Psychiatry. 2025. PMID: 39741440. doi:10.1176/appi.ajp.20231063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。